Y-MABS THERAPEUTICS, INC.

(YMAB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Communiqués de presse de la société Y-MABS THERAPEUTICS, INC.
05/19Y-MABS THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
05/09Y-MABS THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
05/09Y-mAbs Announces First Quarter Financial Results and Recent Corporate Developments
AQ
05/03Y-mAbs to Announce First Quarter 2022 Financial and Operating Results on May 9, 2022
AQ
04/27Y MABS THERAPEUTICS : mAbs Announces Executive Management Changes and Provides 2022 Revenu..
PU
04/27Y-MABS THERAPEUTICS, INC. : Change in Directors or Principal Officers, Other Events, Finan..
AQ
04/27Y-mAbs Announces Executive Management Changes and Provides 2022 Revenue Guidance and Fi..
AQ
04/08Y-mAbs Announces Presentation of SADA Technology at AACR
AQ
04/04Y-mAbs Announces Submission of Omburtamab Biologics License Application to FDA
AQ
04/01Y MABS THERAPEUTICS : mAbs Announces Submission of Omburtamab Biologics License Applicatio..
PU
04/01Y-MABS THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
04/01Y-mAbs Announces Submission of Omburtamab Biologics License Application to FDA
AQ
03/01Y-MABS THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION ..
AQ
02/25Y MABS THERAPEUTICS : mAbs Reports Fourth Quarter and Full ear 2021 Financial Results and ..
PU
02/24Y-mAbs Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate..
AQ
02/17Y-mAbs to Announce 2021 Financial and Operating Results on February 24, 2022
AQ
02/14Y-mAbs Announces Completion of Pre-BLA Meeting with FDA for Omburtamab
AQ
02/11Y MABS THERAPEUTICS : mAbs Announces Completion of Pre-BLA Meeting with FDA for Omburtamab..
PU
02/11Y-MABS THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
02/11Y-mAbs Announces Completion of Pre-BLA Meeting with FDA for Omburtamab
AQ
01/05Y-mAbs Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
AQ
2021Y MABS THERAPEUTICS : Management Change/Compensation - Form 8-K
PU
2021Y-MABS THERAPEUTICS, INC. : Change in Directors or Principal Officers, Financial Statement..
AQ
2021UPDATE - Y-mAbs Announces Pipeline Update
GL
2021Y MABS THERAPEUTICS : mAbs Announces Pipeline Update - Form 8-K
PU
2021Y-MABS THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021Y-mAbs Announces Pipeline Update
AQ
2021Y-mAbs Hosting Virtual Research and Development Day
GL
2021Y-mAbs Hosting Virtual Research and Development Day
GL
2021Y-MABS THERAPEUTICS, INC. : Change in Directors or Principal Officers, Financial Statement..
AQ
2021Y-mAbs Announces Third Quarter Financial Results and Recent Corporate Developments - Fo..
PU
2021Y-mAbs Announces Third Quarter Financial Results and Recent Corporate Developments
AQ
2021Y-MABS THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
2021Y-mAbs Provides Regulatory Update on Omburtamab for the Treatment of Patients with Neur..
PU
2021Y-MABS THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021Y-mAbs Provides Regulatory Update on Omburtamab for the Treatment of Patients with Neur..
AQ
2021Y-mAbs to Announce Third 2021 Financial and Operating Results on November 4, 2021
AQ
2021Y MABS THERAPEUTICS : mAbs 177Lu-omburtamab-DTPA for the Treatment of Patients with Medull..
AQ
2021Y MABS THERAPEUTICS : mAbs' 177Lu-omburtamab-DTPA for the Treatment of Patients with Medul..
PU
2021Y-MABS THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021Y MABS THERAPEUTICS : mAbs' 177Lu-omburtamab-DTPA for the Treatment of Patients with Medul..
AQ
2021Y MABS THERAPEUTICS : mAbs Announces Data to be Presented at SIOP 2021
AQ
2021Y MABS THERAPEUTICS : mAbs Announces Priorit Review of BLA for DANELZA (naxitamab-gqgk) in..
AQ
2021Y MABS THERAPEUTICS : mAbs Announces Priorit Review of BLA for DANELZA® (naxitamab-gqgk) i..
PU
2021Y MABS THERAPEUTICS : mAbs to Host Ke Opinion Leader Webinar on DANELZA (naxitamab-gqgk) F..
AQ
2021Y-MABS THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021Y MABS THERAPEUTICS : mAbs Announces Priorit Review of BLA for DANELZA® (naxitamab-gqgk) i..
AQ
2021Y MABS THERAPEUTICS : mAbs to Host Ke Opinion Leader Webinar on DANELZA® (naxitamab-gqgk) ..
AQ
2021Y MABS THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Resu..
AQ
2021Y MABS THERAPEUTICS : mAbs Announces Second Quarter Financial Results and Recent Corporate..
AQ
2021Y-mAbs to Announce Second Quarter 2021 Financial and Operating Results on August 5, 202..
GL
2021Y MABS THERAPEUTICS : mAbs Announces NMPA Submission of BLA for DANELZA (naxitamab-gqgk) i..
AQ
2021Y MABS THERAPEUTICS : mAbs Announces NMPA Submission of BLA for DANELZA® (naxitamab-gqgk) ..
PU
2021Y-MABS THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021Y-mAbs Announces NMPA Submission of BLA for DANYELZA® (naxitamab-gqgk) in China
GL
2021Y-MABS THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021Y-mAbs' 177Lu-omburtamab-DTPA for the Treatment of Patients with Medulloblastoma Receiv..
GL
2021Y MABS THERAPEUTICS : mAbs' 177Lu-omburtamab-DTPA for the Treatment of Patients with Medul..
PU
2021Y MABS THERAPEUTICS : mAbs Provides Regulator Update on Omburtamab for the Treatment of Pa..
PU
2021Y-MABS THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021Y MABS THERAPEUTICS : mAbs Provides Regulator Update on Omburtamab for the Treatment of Pa..
AQ
2021Y-MABS THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
2021Y MABS THERAPEUTICS : mAbs Announces Frontline Data for DANELZA (naxitamab-gqgk) in High-R..
AQ
2021Y MABS THERAPEUTICS : mAbs Announces Update on Omburtamab for DIPG
AQ
2021Y MABS THERAPEUTICS : Press Release, dated June 4, 2021 issued by Y-mAbs Therapeutics, Inc..
PU
2021Y MABS THERAPEUTICS : mAbs Announces Update on Omburtamab for DIPG (Form 8-K)
PU
2021Y-MABS THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021Y-mAbs Announces Frontline Data for DANYELZA® (naxitamab-gqgk) in High-Risk Neuroblasto..
GL
2021Y MABS THERAPEUTICS : mAbs Announces Update on Omburtamab for DIPG
AQ
2021MEDULLOBLASTOMA PIPELINE : Emerging Therapies and Key pharma players involved by DelveInsi..
AQ
2021Y MABS THERAPEUTICS : mAbs Enters into Exclusive Distribution Agreement with Adium Pharma ..
AQ
2021Y MABS THERAPEUTICS : mAbs Enters into Exclusive Distribution Agreement with Adium Pharma ..
PU
2021Y-MABS THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021Y-mAbs Enters into Exclusive Distribution Agreement with Adium Pharma S.A. for DANYELZA..
GL
2021Y-MABS THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
1  2  3Next
Upcoming event on Y-MABS THERAPEUTICS, INC.